Founded in 2015, CardiNor is a diagnostics company leveraging the biomarker secretoneurin (SN) to address the unmet need for improved risk stratification and prognosis in heart failure patients. The company achieved CE-IVD registration for its SN ELISA assay in 2021 and is focused on commercializing the test in Europe and the US through established distribution agreements. Following its acquisition by IC Targets AS in 2025, CardiNor aims to integrate its low-cost SN blood test with advanced cardiac MRI imaging for a comprehensive heart failure diagnostic solution.
CardiovascularHeart Failure
Technology Platform
Patented blood biomarker platform centered on secretoneurin (SN), a neuropeptide indicator of cardiac stress and arrhythmic risk, with CE-marked ELISA and high-throughput bead-based assay formats.
Funding History
2
Total raised:$10M
Series A$8MUndisclosed
Seed$2MUndisclosed
Opportunities
The integration with IC Targets' MRI contrast agent creates a unique, synergistic diagnostic pathway for heart failure, potentially capturing more value per patient.
The global need for better heart failure prognosis tools and the test's applicability across ejection fraction spectra present a large addressable market.
Expansion into the US and other international markets through distribution agreements offers significant growth potential.
Risk Factors
Commercial success depends on overcoming entrenched competitors like BNP/NT-proBNP and securing favorable reimbursement.
Clinical adoption is a slow process requiring further studies and guideline inclusion.
The company faces integration risks following its recent acquisition and must execute its distribution strategy effectively in diverse markets.
Competitive Landscape
CardiNor competes with established natriuretic peptide tests (BNP/NT-proBNP) and other emerging biomarkers in the cardiovascular diagnostics space. Its key differentiation is secretoneurin's unique link to sympathetic activation and arrhythmic risk, providing prognostic information incremental to standard markers, as evidenced in clinical trials like GISSI-HF.
